AtaCor Enrols First Patient in Pivotal Trial of Extravascular ICD System for Cardiac Rhythm Management

The ALARION-EV trial will evaluate AtaCor Medical’s investigational parasternal extravascular implantable cardioverter-defibrillator (EV-ICD) system, designed to provide an alternative approach to traditional ICD therapy for patients at risk of life-threatening arrhythmias.

AtaCor Medical has enrolled the first patient in its pivotal ALARION-EV clinical trial evaluating its investigational extravascular implantable cardioverter-defibrillator (EV-ICD) system, marking a key milestone in the development of next-generation cardiac rhythm management technology.

The multicentre study will assess the safety and effectiveness of AtaCor’s EV-ICD system in patients who require defibrillation therapy but do not need chronic pacing support for slow heart rhythms.

The trial represents an important step towards expanding ICD treatment options by evaluating a system designed to avoid placement of leads inside the heart and blood vessels.

What Is AtaCor’s Extravascular ICD System?

Traditional implantable cardioverter-defibrillators (ICDs) use leads positioned inside the heart to detect abnormal rhythms and deliver electrical shocks when required.

AtaCor’s EV-ICD approach uses an extravascular design, meaning the system is implanted outside the heart and vascular system.

The investigational system combines:

• AtaCor’s Atala lead, implanted through a small left parasternal incision with electrodes positioned against the pericardium.

• Abbott’s pulse generator, positioned in either a lateral or pectoral device pocket.

The company believes this approach could provide an alternative option for patients requiring defibrillation therapy while reducing some limitations associated with traditional transvenous ICD systems.

ALARION-EV Pivotal Trial Design

The prospective, multicentre, single-arm ALARION-EV study will enrol approximately 280 patients across up to 40 clinical sites in the United States and the Netherlands.

The trial is designed for patients who require ICD therapy but do not require chronic pacing for bradycardia.

Researchers will evaluate the safety and effectiveness of the investigational parasternal EV-ICD system through at least six months of follow-up.

Data generated from the study are expected to support a future Premarket Approval (PMA) submission to the US Food and Drug Administration (FDA).

Advancing Next-Generation Cardiac Rhythm Management

AtaCor Medical said the first patient treatment represents a significant milestone in its efforts to develop new approaches to cardiac rhythm management.

Rick Sanghera, CEO of AtaCor Medical, said the achievement reflected the company’s commitment to advancing extravascular therapies designed to improve patient outcomes.

The AtaCor-Abbott EV-ICD system remains investigational and has not received regulatory approval or commercial availability.

Growing Interest in Implantable Cardiac Devices

The development of alternative ICD technologies comes as demand for advanced cardiac rhythm management solutions continues to grow.

Implantable cardioverter-defibrillators remain a critical therapy for preventing sudden cardiac death in patients at risk of dangerous ventricular arrhythmias.

However, innovation in the field is increasingly focused on improving implantation techniques, reducing procedural complexity and developing technologies that minimise reliance on traditional transvenous approaches.

Why the ALARION-EV Trial Matters

Successful results from the ALARION-EV study could support the development of a new category of extravascular ICD technology.

By evaluating whether an EV-ICD system can provide effective defibrillation therapy without traditional intracardiac leads, AtaCor aims to address ongoing challenges within cardiac rhythm management and expand treatment options for patients requiring implantable defibrillator therapy.

Summary

AtaCor Medical has enrolled the first patient in its ALARION-EV pivotal clinical trial evaluating an investigational extravascular implantable cardioverter-defibrillator (EV-ICD) system.

The study will assess the safety and effectiveness of AtaCor’s parasternal EV-ICD technology, which combines the company’s Atala lead with Abbott’s pulse generator.

If successful, the trial could support regulatory submission and advance the development of next-generation cardiac rhythm management solutions.

---

Discover how nuaxia can support your next medical education initiative:

• Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector 

• Contact us on: support@nuaxia.com